| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Idiopathic pulmonary fibrosis (IPF) is a progressive and devastating chronic lung condition with poor prognosis; mean length of survival from time of diagnosis is 2.8-4.2 years.Current agents for treatment of IPF, such as steroids and immunosuppressants, have not been found to improve prognosis.In this study, I identified stress proteins that suppress the onset and progression of IPF, and elucidated the molecular mechanism. I also proposed a new candidate for IPF therapy from a library of medicines already in clinical use. Furthermore, for drug-induced pulmonary fibrosis, we also constructed an animal model focusing on inflammation and examined the effect of stress proteins on the model.
|
